Published on in Vol 2, No 3 (2021): Jul-Sep

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/33496, first published .
Authors' Response to Peer Reviews of “Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study”

Authors' Response to Peer Reviews of “Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study”

Authors' Response to Peer Reviews of “Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study”

Mark Jarrett   1 * , MBA, MD ;   Warren Licht   1 * , MD ;   Kevin Bock   1 * , MHCDS, MD ;   Zenobia Brown   1 * , MPH, MD ;   Jamie Hirsch   1 * , MA, MSB, MD ;   Kevin Coppa   2 * , BSc ;   Rajdeep Brar   1 * , MD ;   Stephen Bello   2 * , PA, MHCDS ;   Ira Nash   1 * , MD

1 Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hofstra University, Hempstead, NY, United States

2 Northwell Health, New Hyde Park, NY, United States

*all authors contributed equally

Corresponding Author:

  • Mark Jarrett, MBA, MD
  • Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
  • Hofstra University
  • 500 Hofstra University
  • Hempstead, NY, 11549
  • United States
  • Phone: 1 516-463-7516
  • Email: mjarrett@northwell.edu